A5010046486- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Head and Neck Cancer Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Ubiquitin and proteasome pathways
- Radiomics and Machine Learning in Medical Imaging
- DNA Repair Mechanisms
- Advanced Radiotherapy Techniques
- Glycosylation and Glycoproteins Research
- Head and Neck Surgical Oncology
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Management of metastatic bone disease
- Histiocytic Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Epigenetics and DNA Methylation
- Semiconductor materials and devices
- Cancer Diagnosis and Treatment
- Advanced biosensing and bioanalysis techniques
- Genital Health and Disease
Princess Margaret Cancer Centre
2018-2025
University of Toronto
2019-2025
University Health Network
2019-2025
Memorial Sloan Kettering Cancer Center
2013-2024
Canada Research Chairs
2022-2024
The King's College
2024
King's College Hospital
2024
Health Net
2021
Toronto General Hospital
2021
3E (Belgium)
2017
PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for cell lung cancer (SCLC). Identification predictors response would advance our understanding, and guide clinical application, this therapeutic strategy.Efficacy olaparib, rucaparib, veliparib, as well etoposide cisplatin in SCLC lines, gene expression correlates, was analyzed using public datasets. HRD genomic scar scores were calculated from Affymetrix SNP 6.0 arrays. In vitro talazoparib efficacy measured by...
IntroductionThe use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk toxicity. This study (BLINDED FOR REVIEW) aimed determine maximally tolerated dose (MTD) SBRT ultra-central (UC) non-small cell lung carcinoma (NSCLC), using time-to-event continual reassessment methodology (TITE-CRM).MethodsPatients T1-3N0M0 (≤ 6 cm) NSCLC were eligible. The MTD was defined as ≤ 30% rate grade (G) 3-5...
Insufficient chemotherapy response and rapid disease progression remain concerns for small-cell lung cancer (SCLC). Oncologists rely on serial CT scanning to guide treatment decisions, but this cannot assess in vivo target engagement of therapeutic agents. Biomarker assessments biopsy material do not contemporaneous expression, intratumoral drug exposure, or drug-target engagement. Here, we report the use PARP1/2-targeted imaging measure PARP inhibitors vivo. Using a panel clinical...
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a critical need for novel therapies. Our goal was to determine whether PARP inhibition could sensitize SCLC cells ionizing radiation (IR) and if so, the contribution of trapping radiosensitization.Experimental Design: Short-term viability assays clonogenic survival (CSA) were used assess radiosensitization in 6 lines. Doses veliparib talazoparib equivalent enzymatic inhibitory activity but differing identified compared...
The role of radiotherapy (RT) in the treatment patients with anaplastic thyroid cancer (ATC) for local tumor control is critical because mortality often secondary to complications volume rather than metastatic disease. Herein, authors report long-term outcomes RT ATC.A total 104 histologically confirmed ATC were identified who presented study institution between 1984 and 2017 received curative-intent or postoperative RT. Locoregional progression-free survival (LPFS), overall (OS), distant...
Small cell lung cancer (SCLC) is an aggressive disease with overall five-year survival rate of <10%. Treatment for SCLC cisplatin/etoposide chemotherapy (C/E) +/- radiotherapy (RT) has changed modestly over several decades. The ubiquitin-proteasome system underexplored therapeutic target SCLC. We preclinically evaluated TAK-243, a first-in-class small molecule E1 inhibitor against UBA1.We assessed TAK-243 in 26 cell-lines as monotherapy and combined C/E, the PARP-inhibitor, olaparib,...
Brain metastases are common in patients with limited-stage small cell lung cancer (LS-SCLC) due to the inability of most chemotherapeutics penetrate blood-brain barrier. Prophylactic cranial irradiation (PCI) is therefore recommended for use a good response concurrent chemoradiotherapy. However, PCI not always delivered; therefore, we investigated reasons omission who underwent therapy curative intent.We retrospectively reviewed all LS-SCLC were treated intent at our institution. Overall...
Abstract Background Langerhans cell histiocytosis (LCH) is a rare disorder of histiocyte proliferation. Previous case studies suggest higher prevalence hematologic and solid malignancies among LCH patients, possibly due to treatment with tumorigenic agents such as etoposide. We report the first large, single‐institution experience adult patients additional study characteristics these patients. Methods identified 132 consecutive >18 years age histologically confirmed at our center between...
Highlights•A gap in knowledge exists regarding the role of PCI for ES-SCLC patients treated with CTRT.•For all CTRT, was independently associated improved OS and lower brain metastasis incidence compared to omission PCI.•Improved seen who received post-chemotherapy MRIs.•PCI more commonly delivered younger concerns neurotoxicity being most reported reason PCI.AbstractBackgroundThe prophylactic cranial irradiation (PCI) is not well-defined extensive-stage SCLC (ES-SCLC) conflicting results...